Download Files:

AZD8931 diFuMaric acid

SKU T8751-1 mL * 10 mM (in DMSO) Category Small Compound Brand: TargetMol

Price range: 128 CAD through 1,808 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

1 mg 1 mL * 10 mM (in DMSO)10 mg 100 mg 200 mg 25 mg 5 mg 50 mg

Clear

Products Details

Product Description

– AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T8751

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C31H33ClFN5O11

References

– Zhaomei Mu,Teresa Klinowska,Xiaoshen Dong,et al.AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.J Exp Clin Cancer Res. 2014 May 30;33(1):47.

CAS Number

– 1196531-39-1

Molecular Weight

– C31H33ClFN5O11

Compound Purity

– 0.9992

SMILES

– OC(=O)C=CC(O)=O.OC(=O)C=CC(O)=O.CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC

Pathway

– JAK/STAT signaling|||Angiogenesis|||Tyrosine Kinase/Adaptors

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.